AbbVie (ABBV) Tops Q3 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $1.86, $0.08 better than the analyst estimate of $1.78. Revenue for the quarter came in at $15.78 billion versus the consensus estimate of $15.58 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $10.61-$0.65, versus the consensus of $10.86.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• Morgan Stanley Resumes Carrefour SA (CA:FP) (CRRFY) at Overweight
• Citizens Starts NRC Group Holdings Corp. (NRCG) at Market Outperform